Nanomedicine: Nanotechnology, Biology and Medicine
Volume 1, Issue 1 , Pages 47-51, March 2005

The pathway to commercialization for nanomedicine

  • Ted Flynn, MPA

      Affiliations

    • Potomac Investment Capital, LLC, Sterling, Virginia
  • ,
  • Chiming Wei, MD, PhD

      Affiliations

    • Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • Corresponding Author InformationCorresponding author. 600 N Wolfe St/Blalock 1206, Baltimore, MD 21205.

Received 2 October 2004; accepted 23 November 2004.

Abstract 

Nanomedicine is a global opportunity that will change the face of medicine and drug delivery in the next 20 years. To date, US firms have focused primarily on the science and less on the commercial application of nanomedicine. As a result, there remain significant obstacles in bringing a nanomedicine product to market. Overcoming those obstacles will require a multidisciplinary approach to commercialization. This article will look at the emerging nanomedicine market, the current view from the investment community, and some of the obstacles facing the commercialization of nanomedicine science.

Key words: Nanomedicine, Nanotechnology, Commercialization, Business, Development

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 10.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1549-9634(05)00013-4

doi:10.1016/j.nano.2004.11.010

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 1, Issue 1 , Pages 47-51, March 2005